Category Archives: Nanomedicine

Exopharm: exosomes seen as an alternative to lipid nanoparticles (LNPs) and adeno-associated viral vectors (#AAVs) for targeted multi-dose delivery of modern medicines and vaccines

MELBOURNE, Australia, 3-Feb-2022 — /EPR HEALTHCARE NEWS/ — Australian technologist Dr Ian Dixon founded Exopharm in 2013 with the vision to harness the unique properties of exosomes as a new class of medicine. Dixon’s decisive early entry into exosome therapeutics is now bearing fruits.

Less than 10 years after its founding, Exopharm possesses a granted US patent for its key exosome manufacturing technology, LEAP™, and has run successful first-in-human clinical trials demonstrating the safety of its exosome products.

Exosomes have the potential to revolutionise medicine in many areas, including delivery of gene therapies into cell nucleus for rare and common genetic disorders, improving therapeutic window of small and large molecules by cell targeting, and by selective cellular delivery of next-generation DNA/RNA products.

In 2022, excitement around exosomes has converged on exosomes as an alternative to lipid nanoparticles (LNPs) and adeno-associated viral vectors (AAVs) for targeted multi-dose delivery of modern medicines and vaccines. Drug delivery accounts for a significant slice of the global pharmaceutical industry spend –around US$160b p.a. and growing strongly – and exosomes represent nature’s way to deliver a bioactive cargo into cells efficiently and safely.

Primed for growth

Dixon’s establishment of a specialist exosome medicines company has been followed by US based Codiak Biociences in 2015 (established by Arch Ventures) and Oxford based Evox Therapeutics in 2016. Today, only two dedicated exosome companies are listed on the public markets: Codiak (NASDAQ: CDAK) with a market cap of around US$200m; and Exopharm (ASX: EX1) with a market cap of around A$73m at the time of writing this article.

The field of exosome medicines is attracting the attention of financiers and pharmaceutical industry leaders. In late 2021, multinational pharmaceutical manufacturing services company Lonza jumped into exosome manufacture, a sign that they see big things over the horizon.

Over the past 9 years, Exopharm has grown and evolved but remains true to Dixon’s vision of exosome medicine development. The company now employs around 40 people most in its Melbourne, Australia, facility. Exopharm has built a toolbox of exosome technologies and knowhow which, in addition to the LEAP™ scalable exosome manufacturing platform, includes exosome analytical tools (Exoria) and technologies to load exosomes with a specific therapeutic cargo (LOAD) and target exosomes to select cells (EVPS).

Our business development team is attracting the attention of similar innovative biopharmaceutical and biomanufacturing companies, and validating the Exopharm technologies via collaboration research agreements.

Exopharm is not simply a technology company, however. Exopharm is pursuing a pipeline driven platform technology strategy, on the way to generating a revenue stream from technology out-licensing while developing its own exosome medicines for selected markets. More news on its pipeline products is expected to be ready for release later in CY ’22.

The Exopharm team has grown and changed to becoming more international in focus, improving on messaging and communications with the wider pharmaceutical industry. In 2021 Dr Jenn King joined the Board of Exopharm, bringing a wealth of big pharma and US biotech experience with her.

In 2022 we look to engage with more experts, as members of our advisory panels, as consultants, executives or Key Opinion Leaders. Please reach out to us if you want to be part of our vision.

At the company’s 10-year anniversary in late 2023, Exopharm will be a key part of the exosome medicines revolution.

SOURCE: EuropaWire

Pharmacy College Teacher And Students Write On A Common Blog To Share Quickly Pharmaceutical Industry Technology Developments

Dr.Martin a former teacher in pharmacy college and now a director in a worlds biggest pharmaceutical company, was favorite amongst his students and colleagues for his innovative ideas on research and development teaching subjects on pharmaceutical and biotechnology.

One day he and his students on their last day in the college after completing the examinations in course in pharmacy , decided to stay in touch with each other ,and share technical knowledge regularly with each other , they in this process started writing on a common blog whoguideline.blogspot.com on the subjects on their own profession of pharmaceutical industry and biotechnology

This blog is now updated by then students and now top pharmaceutical industry professionals they never knew that this platform will soon become a favorite world wide amongst worlds pharmaceutical industry and pharmacists.

In pharmaceutical industry technology is moving so fast and to keep one self updated day today is a difficult task unless one join a group of a pharmaceutical association or a forums , where one is required to attend meetings and seminars there & one can discuss the latest happening in pharmaceutical industry.

The students says advantage of writing on this blog is just like attending a seminar on pharmaceutical or biotechnology industry , we write on vivid topics and the technical articles are very informative.There is not a single topic on pharmaceutical technology which is left untouched on this blog , be it biotechnology , microbiology or novel drug delivery system or latest happening in pharmaceutical regulatory affairs and latest news in pharma industry is published regularly.

Dr.Martin the cheap author and editor of the blog said that we started writing on our blog to share our knowledge amongst under graduate and post graduate , and doctoral students and industry professionals , as it is best tool to publish and share the knowledge quickly and easily , in this process so far about 1161 pharmaceutical industry professionals and students and have successfully subscribed to the blog , and this blog is now one of the preferred resource of technical knowledge on all topics in pharmaceutical industry.

Via EPR Network
More Healthcare press releases